Insider Selling: Edwards Lifesciences Corp (NYSE:EW) CFO Sells $1,868,466.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) CFO Scott B. Ullem sold 26,700 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $69.98, for a total value of $1,868,466.00. Following the completion of the sale, the chief financial officer now owns 53,814 shares of the company’s stock, valued at $3,765,903.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

NYSE:EW opened at $67.82 on Friday. The company has a current ratio of 3.36, a quick ratio of 2.47 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $41.85 billion, a PE ratio of 38.90, a price-to-earnings-growth ratio of 2.59 and a beta of 0.86. The firm’s 50 day moving average is $103.31 and its 200 day moving average is $81.53. Edwards Lifesciences Corp has a 12 month low of $51.51 and a 12 month high of $82.55.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Edwards Lifesciences had a net margin of 24.71% and a return on equity of 31.83%. Edwards Lifesciences’s revenue was up 13.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.44 EPS. Research analysts predict that Edwards Lifesciences Corp will post 1.65 earnings per share for the current year.

Several analysts have recently commented on EW shares. Barclays restated an “underweight” rating and issued a $51.67 target price (down from $55.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. They noted that the move was a valuation call. Morgan Stanley reduced their target price on Edwards Lifesciences from $83.33 to $83.00 and set an “overweight” rating for the company in a research note on Monday, June 29th. Stifel Nicolaus raised their target price on Edwards Lifesciences from $76.67 to $85.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Deutsche Bank dropped their price target on shares of Edwards Lifesciences from $81.67 to $75.00 and set a “hold” rating on the stock in a research report on Wednesday, April 22nd. Finally, SVB Leerink cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Sunday, April 19th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $82.52.

Large investors have recently bought and sold shares of the stock. Procyon Private Wealth Partners LLC lifted its holdings in Edwards Lifesciences by 276.3% during the 1st quarter. Procyon Private Wealth Partners LLC now owns 143 shares of the medical research company’s stock worth $27,000 after purchasing an additional 105 shares in the last quarter. 1776 Wealth LLC lifted its holdings in Edwards Lifesciences by 97.6% during the 1st quarter. 1776 Wealth LLC now owns 162 shares of the medical research company’s stock worth $30,000 after purchasing an additional 80 shares in the last quarter. Balentine LLC purchased a new stake in Edwards Lifesciences during the 1st quarter worth about $32,000. M&R Capital Management Inc. lifted its holdings in Edwards Lifesciences by 200.0% during the 2nd quarter. M&R Capital Management Inc. now owns 480 shares of the medical research company’s stock worth $33,000 after purchasing an additional 320 shares in the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in Edwards Lifesciences by 200.0% during the 2nd quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 600 shares of the medical research company’s stock worth $41,000 after purchasing an additional 400 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: What is a recession?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.